tradingkey.logo

Qiagen NV

QGEN
View Detailed Chart
50.950USD
-0.280-0.55%
Close 02/06, 16:00ETQuotes delayed by 15 min
11.03BMarket Cap
26.20P/E TTM

Qiagen NV

50.950
-0.280-0.55%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.55%

5 Days

-5.07%

1 Month

+8.20%

6 Months

+7.29%

Year to Date

+13.11%

1 Year

+20.05%

View Detailed Chart

TradingKey Stock Score of Qiagen NV

Currency: USD Updated: 2026-02-06

Key Insights

Qiagen NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 54.16.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Qiagen NV's Score

Industry at a Glance

Industry Ranking
18 / 392
Overall Ranking
108 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Qiagen NV Highlights

StrengthsRisks
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.09B.
Undervalued
The company’s latest PE is 26.20, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 153.75M shares, decreasing 22.76% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 5.10K shares of this stock.

Analyst Rating

Based on 18 analysts
Hold
Current Rating
54.159
Target Price
+5.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Qiagen NV News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Qiagen NV Info

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Ticker SymbolQGEN
CompanyQiagen NV
CEOBernard (Thierry)
Websitehttps://www.qiagen.com/
KeyAI